A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

Lifestyle adjustments can help prevent UTIs. While not a proven cure, cranberry products and D-mannose supplements may help ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving treatment options for millions of women.

The drug gepotidacin, which will be sold under the brand name Blujepa, is approved for females age 12 and older with uncomplicated UTIs. Recurrent UTIs are common among women, and the bacteria that ...

GSK's Blujepa (gepotidacin) becomes the first in a new class of oral antibiotics to treat uncomplicated UTIs (also known as uUTIs) in almost 30 years, taking aim at infection-causing bacteria ...

GSK plc, announced that the US FDA has approved Blujepa (gepotidacin) for the treatment of female adults (=40 kg) and paediatric patients (=12 years, =40 kg) with uncomplicated urinary tract ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...